Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

The ACA and the Future of the BPCIA (<i>The Center for Biosimilars</i>)

main

08_09 Press Post_The ACA and the Future of BPCIA

Press Post: The ACA and the Future of the BPCIA (The Center for Biosimilars)

The ACA and the Future of the BPCIA (The Center for Biosimilars)

Related Content

FDA Approves Orca Bio’s TREGZI for Allogeneic Hematopoietic Transplants

Celltrion and Teva’s TRUXIMA® Becomes First Interchangeable Rituximab Biosimilar in U.S.

FDA Expands Indication for Vertex’s CASGEVY to Children Aged Two Years and Older

FDA Advisory Committee Votes in Favor of Moderna Flu Vaccine Benefit-Risk Profile

FDA Approves Viridian’s LUMVOA for Thyroid Eye Disease

Janssen Files BPCIA Complaint Against Alvotech Related to Golimumab Biosimilar

Xbrane Biopharma AB and JOINN Biologics US Inc. Partner to Develop Xdarzane

FDA Expands TOFIDENCE® (tocilizumab-bavi) Label to Include CRS and COVID-19

Securities Litigation Against Life Sciences Companies: Recent Trends and Updates

Goodwin Guides Memo Therapeutics AG on Acquisition by Ipsen for Over €700 Million

Goodwin Guides the Underwriters on Taysha’s $230 Million Underwritten Public Offering

Goodwin Guides Astex on Research Collaboration and License Agreement With Genentech for $25 Million Upfront and Up to $490 Million in Milestones

Goodwin Advises Myricx Bio on Acquisition by Novartis to Advance Next-Generation ADC Payloads for Oncology

Goodwin Advises Bionyra Pharma on $165 million Oversubscribed Series A and In-Licensing of Multiple Next-Generation Biologics

Goodwin Guides Oblenio Bio on Closing $62 Million Series B

Goodwin Advises Ollin Biosciences on Oversubscribed $330 Million Series B Financing

Life Sciences

Life Sciences Patent Prosecution & Counseling

Patent Litigation

Patent Prosecution & Counseling

Patent Trial & Appeal Board

Hatch-Waxman, Biologics and Biosimilars Litigation